lobbying_activities: 1962613

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1962613	479c09d5-1517-40e5-beea-f41f4f6f03be	Q1	PRIME THERAPEUTICS	400339576	PRIME THERAPEUTICS	2017	first_quarter	PHA	Generic drug user fee act - provisions to ensure greater market competition for generics. Biosimilar drug user fee act - ensuring greater competition in the biosimilar market. S.469/H.R.1245: Affordable and Safe Prescription Drug Importation Act. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act - issues relating to ensuring a competitive drug marketplace. S.778:Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines.	HOUSE OF REPRESENTATIVES,SENATE		40000	0	0	2017-04-19T16:28:39.407000-04:00